Regorafenib Assessment in Refractory Advanced Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RegARd-C
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 07 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
- 07 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.